Brian Russell

Fagron Sterile Services US operates two cGMP compliant DEA/FDA-registered and inspected 503B Outsourcing Facilities (Wichita, KS & Boston, MA) delivering a reliable supply sterile of medications to patient-focused healthcare facilities across the United States. FSS specializes in Sterile-to-Sterile, API-to-Sterile, and Biologics, offering an robust portfolio of preparations including ready-to-administer IV bags and OR syringes, pain management, ophthalmics, dialysis, urology, and specialty solutions. OUR STORY: Together we create the future of personalizing medicine. Founded in 1990, in the Netherlands, Fagron engineered one of the largest quality networks, with certified auditors performing supplier qualifications, serving 35 countries, to deliver high-quality products to more than 200,000+ customers worldwide. In doing so, Fagron has become the global leader in pharmaceutical compounding. In 2010, Fagron entered the North American market. As part of the only vertically integrated pharmaceutical company dedicated to sterile compounding, Fagron's 503B facilities (FSS) provide pharmaceutical outsourcing solutions on a comprehensive level to meet customer needs across the continuum of care. As a forward-thinking pharmaceutical supplier, Fagron recognized the opportunity to serve our customers better by acquiring JCB Laboratories, in December, 2013. JCB Labs was at the forefront of shaping industry standards in sterile preparations for nearly two decades and was one of the first companies in the country to register with the FDA. Building off JCB’s experience, Fagron built FSS US, a state-of-the-art manufacturing facility in Wichita, KS, because we believe in the need for regulated sterile preparations. In 2022, Fagron added a second state-of-the-art facility in Boston, MA, through the acquisition of Fresenius Kabi's compounding division. Choose Quality. Choose Consistency. Choose Fagron Sterile Services US, A 503B Outsourcing Solution You Can Rely On!